🇺🇸 BNT162b2 (Omi JN.1) in United States

BNT162b2 (Omi JN.1) (bnt162b2-omi-jn-1) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

BNT162b2 (Omi JN.1) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease approved in United States

Frequently asked questions

Is BNT162b2 (Omi JN.1) approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for BNT162b2 (Omi JN.1) in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does BNT162b2 (Omi JN.1) cost in United States?

annual_list: USD 4361.33 per year. Final patient cost depends on reimbursement and any patient access scheme.